Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity And Safety Of An Alum-Adjuvanted Inactivated H7N9 Influenza Vaccine

Trial Profile

Immunogenicity And Safety Of An Alum-Adjuvanted Inactivated H7N9 Influenza Vaccine

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs H7N9 influenza vaccine-Shanghai Institute Of Biological Products (Primary)
  • Indications Influenza A virus H7N9 subtype
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 05 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2019.
    • 18 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top